<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40791947</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>Recent advancements and comprehensive analyses of butyric acid in cardiovascular diseases.</ArticleTitle><Pagination><StartPage>1608658</StartPage><MedlinePgn>1608658</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1608658</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2025.1608658</ELocationID><Abstract><AbstractText>Cardiovascular disease (CVD) remains a predominant cause of morbidity and mortality globally, characterized by pathological mechanisms that encompass inflammation, oxidative stress, metabolic disturbances and immune dysregulation. Recently, the influence of gut microbiota and its metabolites on the onset and progression of CVD has garnered significant attention. Short-chain fatty acids (SCFAs), particularly butyrate, are the primary products of gut microbial fermentation of dietary fiber. Butyrate is instrumental in maintaining intestinal barrier function and immune homeostasis and exhibits notable anti-inflammatory, antioxidant, and metabolic regulatory potentials in cardiovascular diseases. Nonetheless, the precise molecular mechanisms of butyrate in various cardiovascular diseases and its clinical translational value necessitate a systematic review of the literature. This study conducted a comprehensive search of databases, such as PubMed and Web of Science, to synthesize recent basic and clinical research on butyrate and cardiovascular diseases, focusing on its role in hypertension, atherosclerosis, coronary artery disease, atrial fibrillation, diabetic cardiomyopathy, and heart failure. The findings indicate that butyrate can influence cardiovascular health through multiple pathways, including the modulation of G protein-coupled receptors (GPCRs), histone deacetylases (HDACs), and peroxisome proliferator-activated receptors (PPARs). Although numerous experimental studies have corroborated the protective effects of butyrate in cardiovascular diseases, its clinical translation remains challenging owing to factors such as optimal administration route, dose optimization, and individualized treatment strategies. Future research should integrate large-scale population cohort analyses and randomized controlled trials (RCTs) to ascertain the precise efficacy of butyrate in the prevention and treatment of cardiovascular diseases and explore its potential as a novel therapeutic target.</AbstractText><CopyrightInformation>&#xa9; 2025 Xu, Liu, Wang, Li, Jiang and Xu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine, The First People's Hospital of Zunyi, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaomin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine, The First People's Hospital of Zunyi, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhengming</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine, The First People's Hospital of Zunyi, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xianghui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine, The First People's Hospital of Zunyi, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Qianfeng</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine, The First People's Hospital of Zunyi, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiovascular Medicine, The First People's Hospital of Zunyi, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atherosclerosis</Keyword><Keyword MajorTopicYN="N">butyric acid</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">obesity</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40791947</ArticleId><ArticleId IdType="pmc">PMC12336178</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2025.1608658</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kwan GF, Mayosi BM, Mocumbi AO, Miranda JJ, Ezzati M, Jain Y, et al. Endemic cardiovascular diseases of the poorest billion. Circulation. (2016) 133:2561&#x2013;75. 10.1161/circulationaha.116.008731</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.116.008731</ArticleId><ArticleId IdType="pubmed">27297348</ArticleId></ArticleIdList></Reference><Reference><Citation>Duttaroy AK. Role of gut microbiota and their metabolites on atherosclerosis, hypertension and human blood platelet function: a review. Nutrients. (2021) 13:144. 10.3390/nu13010144</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13010144</ArticleId><ArticleId IdType="pmc">PMC7824497</ArticleId><ArticleId IdType="pubmed">33401598</ArticleId></ArticleIdList></Reference><Reference><Citation>Beam A, Clinger E, Hao L. Effect of diet and dietary components on the composition of the gut microbiota. Nutrients. (2021) 13:2795. 10.3390/nu13082795</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13082795</ArticleId><ArticleId IdType="pmc">PMC8398149</ArticleId><ArticleId IdType="pubmed">34444955</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. (2022) 183:109119. 10.1016/j.diabres.2021.109119</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2021.109119</ArticleId><ArticleId IdType="pmc">PMC11057359</ArticleId><ArticleId IdType="pubmed">34879977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartrand DJ, Murphy-Despr&#xe9;s A, Alm&#xe9;ras N, Lemieux I, Larose E, Despr&#xe9;s JP. Overweight, obesity, and CVD risk: a focus on visceral/ectopic fat. Curr Atheroscler Rep. (2022) 24:185&#x2013;95. 10.1007/s11883-022-00996-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11883-022-00996-x</ArticleId><ArticleId IdType="pubmed">35235165</ArticleId></ArticleIdList></Reference><Reference><Citation>La Sala L, Pontiroli AE. Prevention of diabetes and cardiovascular disease in obesity. Int J Mol Sci. (2020) 21:8178. 10.3390/ijms21218178</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218178</ArticleId><ArticleId IdType="pmc">PMC7663329</ArticleId><ArticleId IdType="pubmed">33142938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CJ, Sears CL, Maruthur N. Gut microbiome and its role in obesity and insulin resistance. Ann N Y Acad Sci. (2020) 1461:37&#x2013;52. 10.1111/nyas.14107</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14107</ArticleId><ArticleId IdType="pubmed">31087391</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheang WS, Chen X. Protective effects of piceatannol on cardiovascular diseases. PHYTONutrients. (2024) 3:36&#x2013;45. 10.62368/pn.v3i.30</Citation><ArticleIdList><ArticleId IdType="doi">10.62368/pn.v3i.30</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan CW, Wong CN, Pin WK, Wong MH, Kwok CY, Chan RY, et al. Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-&#x3b1; in hypercholesterolemic rats induced with a high-cholesterol diet. Phytother Res. (2013) 27:545&#x2013;51. 10.1002/ptr.4751</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.4751</ArticleId><ArticleId IdType="pubmed">22674675</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh A, De Vadder F, Kovatcheva-Datchary P, B&#xe4;ckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. (2016) 165:1332&#x2013;45. 10.1016/j.cell.2016.05.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.041</ArticleId><ArticleId IdType="pubmed">27259147</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. (2014) 12:661&#x2013;72. 10.1038/nrmicro3344</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro3344</ArticleId><ArticleId IdType="pubmed">25198138</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. (1987) 28:1221&#x2013;7. 10.1136/gut.28.10.1221</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.28.10.1221</ArticleId><ArticleId IdType="pmc">PMC1433442</ArticleId><ArticleId IdType="pubmed">3678950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivaprakasam S, Bhutia YD, Yang S, Ganapathy V. Short-chain fatty acid transporters: role in colonic homeostasis. Compr Physiol. (2017) 8:299&#x2013;314. 10.1002/cphy.c170014</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.c170014</ArticleId><ArticleId IdType="pmc">PMC6019286</ArticleId><ArticleId IdType="pubmed">29357130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazime H, Ducasa GM, Santander AM, Brito N, Gonzalez-Horta EE, Quintero MA, et al. DUOX2 activation drives bacterial translocation and subclinical inflammation in IBD-associated dysbiosis. Gut. (2025):1&#x2013;13. 10.1136/gutjnl-2024-334346</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2024-334346</ArticleId><ArticleId IdType="pubmed">40301115</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans LW, Athukorala M, Martinez-Guryn K, Ferguson BS. The role of histone acetylation and the microbiome in phytochemical efficacy for cardiovascular diseases. Int J Mol Sci. (2020) 21:4006. 10.3390/ijms21114006</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21114006</ArticleId><ArticleId IdType="pmc">PMC7313062</ArticleId><ArticleId IdType="pubmed">32503339</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Kamato D, Little PJ, Nakagawa S, Pelisek J, Jin ZG. Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. Pharmacol Ther. (2019) 196:15&#x2013;43. 10.1016/j.pharmthera.2018.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.11.003</ArticleId><ArticleId IdType="pmc">PMC6450782</ArticleId><ArticleId IdType="pubmed">30439455</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Liu Y, Cao J, Wu C, Tang L, Bian W, et al. Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment. Cell Death Discov. (2025) 11:189. 10.1038/s41420-025-02491-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-025-02491-z</ArticleId><ArticleId IdType="pmc">PMC12012105</ArticleId><ArticleId IdType="pubmed">40258841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lymperopoulos A, Suster MS, Borges JI. Short-chain fatty acid receptors and cardiovascular function. Int J Mol Sci. (2022) 23:3303. 10.3390/ijms23063303</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23063303</ArticleId><ArticleId IdType="pmc">PMC8952772</ArticleId><ArticleId IdType="pubmed">35328722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajith TA, Jayakumar TG. Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease. Clin Exp Pharmacol Physiol. (2016) 43:649&#x2013;58. 10.1111/1440-1681.12579</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1440-1681.12579</ArticleId><ArticleId IdType="pubmed">27115677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HJ, Liao HH, Yang Z, Tang QZ. Peroxisome proliferator-activated receptor-<i>&#x3b3;</i> is critical to cardiac fibrosis. PPAR Res. (2016) 2016:2198645. 10.1155/2016/2198645
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/2198645</ArticleId><ArticleId IdType="pmc">PMC4880703</ArticleId><ArticleId IdType="pubmed">27293418</ArticleId></ArticleIdList></Reference><Reference><Citation>Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. (2005) 54:2460&#x2013;70. 10.2337/diabetes.54.8.2460</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.54.8.2460</ArticleId><ArticleId IdType="pubmed">16046315</ArticleId></ArticleIdList></Reference><Reference><Citation>Muralitharan RR, Jama HA, Xie L, Peh A, Snelson M, Marques FZ. Microbial peer pressure: the role of the gut microbiota in hypertension and its complications. Hypertension. (2020) 76:1674&#x2013;87. 10.1161/HYPERTENSIONAHA.120.14473</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.14473</ArticleId><ArticleId IdType="pubmed">33012206</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension. (2015) 65:1331&#x2013;40. 10.1161/HYPERTENSIONAHA.115.05315</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.05315</ArticleId><ArticleId IdType="pmc">PMC4433416</ArticleId><ArticleId IdType="pubmed">25870193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Goel R, Kumar A, Qi Y, Lobaton G, Hosaka K, et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci. (2018) 132:701&#x2013;18. 10.1042/CS20180087</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20180087</ArticleId><ArticleId IdType="pmc">PMC5955695</ArticleId><ArticleId IdType="pubmed">29507058</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, He FJ, Dong Y, Huang Y, Wang C, Harshfield GA, et al. Modest sodium reduction increases circulating short-chain fatty acids in untreated hypertensives: a randomized, double-blind, placebo-controlled trial. Hypertension. (2020) 76:73&#x2013;9. 10.1161/HYPERTENSIONAHA.120.14800</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.14800</ArticleId><ArticleId IdType="pmc">PMC7328301</ArticleId><ArticleId IdType="pubmed">32475312</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilves C, Yeh HC, Maruthur N, Juraschek SP, Miller E, White K, et al. Increases in circulating and fecal butyrate are associated with reduced blood pressure and hypertension: results from the SPIRIT trial. J Am Heart Assoc. (2022) 11:e024763. 10.1161/JAHA.121.024763</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.024763</ArticleId><ArticleId IdType="pmc">PMC9333372</ArticleId><ArticleId IdType="pubmed">35730613</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Han Z, Kong Q, Wang Y, Mou H, Duan X. Clostridium butyricum prevents dysbiosis and the rise in blood pressure in spontaneously hypertensive rats. Int J Mol Sci. (2023) 24:4955. 10.3390/ijms24054955</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24054955</ArticleId><ArticleId IdType="pmc">PMC10002514</ArticleId><ArticleId IdType="pubmed">36902386</ArticleId></ArticleIdList></Reference><Reference><Citation>Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, Petrosino JF, et al. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension. (2016) 67:469&#x2013;74. 10.1161/HYPERTENSIONAHA.115.06672</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.06672</ArticleId><ArticleId IdType="pmc">PMC4713369</ArticleId><ArticleId IdType="pubmed">26711739</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Magee KL, Colon-Perez LM, Larkin R, Liao YS, Balazic E, et al. Impaired butyrate absorption in the proximal colon, low serum butyrate and diminished central effects of butyrate on blood pressure in spontaneously hypertensive rats. Acta Physiol. (2019) 226:e13256. 10.1111/apha.13256</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13256</ArticleId><ArticleId IdType="pmc">PMC7199780</ArticleId><ArticleId IdType="pubmed">30656835</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Arango LF, Barrett HL, McIntyre HD, Callaway LK, Morrison M, Dekker Nitert M, et al. Increased systolic and diastolic blood pressure is associated with altered gut microbiota composition and butyrate production in early pregnancy. Hypertension. (2016) 68:974&#x2013;81. 10.1161/HYPERTENSIONAHA.116.07910</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.116.07910</ArticleId><ArticleId IdType="pubmed">27528065</ArticleId></ArticleIdList></Reference><Reference><Citation>Huart J, Leenders J, Taminiau B, Descy J, Saint-Remy A, Daube G, et al. Gut microbiota and fecal levels of short-chain fatty acids differ upon 24-hour blood pressure levels in men. Hypertension. (2019) 74:1005&#x2013;13. 10.1161/HYPERTENSIONAHA.118.12588</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.118.12588</ArticleId><ArticleId IdType="pubmed">31352822</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A. (2013) 110:4410&#x2013;5. 10.1073/pnas.1215927110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1215927110</ArticleId><ArticleId IdType="pmc">PMC3600440</ArticleId><ArticleId IdType="pubmed">23401498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zhu Q, Lu A, Liu X, Zhang L, Xu C, et al. Sodium butyrate suppresses angiotensin II-induced hypertension by inhibition of renal (pro)renin receptor and intrarenal renin&#x2013;angiotensin system. J Hypertens. (2017) 35:1899&#x2013;908. 10.1097/hjh.0000000000001378</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/hjh.0000000000001378</ArticleId><ArticleId IdType="pmc">PMC11157961</ArticleId><ArticleId IdType="pubmed">28509726</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyszkiewicz M, Gawrys-Kopczynska M, Konopelski P, Aleksandrowicz M, Sawicka A, Kozniewska E, et al. Butyric acid, a gut bacteria metabolite, lowers arterial blood pressure via colon-vagus nerve signaling and GPR41/43 receptors. Pflugers Arch. (2019) 471:1441&#x2013;53. 10.1007/s00424-019-02322-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-019-02322-y</ArticleId><ArticleId IdType="pmc">PMC6882756</ArticleId><ArticleId IdType="pubmed">31728701</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan N, Hori D, Flavahan S, Steppan J, Flavahan NA, Berkowitz DE, et al. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. Physiol Genomics. (2016) 48:826&#x2013;34. 10.1152/physiolgenomics.00089.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00089.2016</ArticleId><ArticleId IdType="pmc">PMC6223570</ArticleId><ArticleId IdType="pubmed">27664183</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen Z, Zhang L, Zhu Y, Deng M, Huang C, et al. Sodium butyrate ameliorates deoxycorticosterone acetate/salt-induced hypertension and renal damage by inhibiting the MR/SGK1 pathway. Hypertens Res. (2021) 44:168&#x2013;78. 10.1038/s41440-020-00548-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-020-00548-3</ArticleId><ArticleId IdType="pubmed">32908237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan Y, Shen YH, Wang J, Wang X, Utama B, Wang J, et al. Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase. J Biol Chem. (2005) 280:16467&#x2013;75. 10.1074/jbc.M412960200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M412960200</ArticleId><ArticleId IdType="pmc">PMC1283144</ArticleId><ArticleId IdType="pubmed">15722551</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. (2007) 204:2449&#x2013;60. 10.1084/jem.20070657</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20070657</ArticleId><ArticleId IdType="pmc">PMC2118469</ArticleId><ArticleId IdType="pubmed">17875676</ArticleId></ArticleIdList></Reference><Reference><Citation>Deussen A, Kopaliani I. Targeting inflammation in hypertension. Curr Opin Nephrol Hypertens. (2023) 32:111&#x2013;7. 10.1097/MNH.0000000000000862</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MNH.0000000000000862</ArticleId><ArticleId IdType="pmc">PMC9872860</ArticleId><ArticleId IdType="pubmed">36476561</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun HJ, Ren XS, Xiong XQ, Chen YZ, Zhao MX, Wang JJ, et al. NLRP3 Inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension. Cell Death Dis. (2017) 8:e3074. 10.1038/cddis.2017.470</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.470</ArticleId><ArticleId IdType="pmc">PMC5680591</ArticleId><ArticleId IdType="pubmed">28981106</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. (2019) 115:776&#x2013;87. 10.1093/cvr/cvy252</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvy252</ArticleId><ArticleId IdType="pmc">PMC6432065</ArticleId><ArticleId IdType="pubmed">30357309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayazid AB, Kim JG, Azam S, Jeong SA, Kim DH, Park CW, et al. Sodium butyrate ameliorates neurotoxicity and exerts anti-inflammatory effects in high fat diet-fed mice. Food Chem Toxicol. (2022) 159:112743. 10.1016/j.fct.2021.112743</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2021.112743</ArticleId><ArticleId IdType="pubmed">34890760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, He G, Peng Y, Zhong W, Wang Y, Zhang B. Sodium butyrate alleviates adipocyte inflammation by inhibiting NLRP3 pathway. Sci Rep. (2015) 5:12676. 10.1038/srep12676</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12676</ArticleId><ArticleId IdType="pmc">PMC4522654</ArticleId><ArticleId IdType="pubmed">26234821</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wei B, Liu X, Shen XZ, Shi P. Microglia, autonomic nervous system, immunity and hypertension: is there a link? Pharmacol Res. (2020) 155:104451. 10.1016/j.phrs.2019.104451</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2019.104451</ArticleId><ArticleId IdType="pubmed">31557524</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei H, Yu C, Zhang C, Ren Y, Guo L, Wang T, et al. Butyrate ameliorates chronic alcoholic central nervous damage by suppressing microglia-mediated neuroinflammation and modulating the microbiome-gut-brain axis. Biomed Pharmacother. (2023) 160:114308. 10.1016/j.biopha.2023.114308</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2023.114308</ArticleId><ArticleId IdType="pubmed">36709599</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, et al. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules. (2018) 8:80. 10.3390/biom8030080</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom8030080</ArticleId><ArticleId IdType="pmc">PMC6163673</ArticleId><ArticleId IdType="pubmed">30142970</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer GRY, Zurek M, Puylaert P, Martinet W. Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets. Nat Rev Cardiol. (2024) 21:312&#x2013;25. 10.1038/s41569-023-00957-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-023-00957-0</ArticleId><ArticleId IdType="pubmed">38163815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JC, Buffa JA, Org E, Wang Z, Levison BS, Zhu W, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem. (2015) 290:5647&#x2013;60. 10.1074/jbc.M114.618249</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.618249</ArticleId><ArticleId IdType="pmc">PMC4342477</ArticleId><ArticleId IdType="pubmed">25550161</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. (2017) 8:845. 10.1038/s41467-017-00900-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00900-1</ArticleId><ArticleId IdType="pmc">PMC5635030</ArticleId><ArticleId IdType="pubmed">29018189</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Zhang S, Wu J, Ye T, Wang S, Wang P, et al. Butyrate-producing bacteria and the gut-heart axis in atherosclerosis. Clin Chim Acta. (2020) 507:236&#x2013;41. 10.1016/j.cca.2020.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.04.037</ArticleId><ArticleId IdType="pubmed">32376324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasahara K, Krautkramer KA, Org E, Romano KA, Kerby RL, Vivas EI, et al. Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol. (2018) 3:1461&#x2013;71. 10.1038/s41564-018-0272-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0272-x</ArticleId><ArticleId IdType="pmc">PMC6280189</ArticleId><ArticleId IdType="pubmed">30397344</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar EC, Leonel AJ, Teixeira LG, Silva AR, Silva JF, Pelaez JM, et al. 
Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NF<i>&#x3ba;</i>B activation. Nutr Metab Cardiovasc Dis. (2014) 24:606&#x2013;13. 10.1016/j.numecd.2014.01.002
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2014.01.002</ArticleId><ArticleId IdType="pubmed">24602606</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen HR, Wang ZY, Shen Z, Liu TT, Guo YD, Gao TL, et al. Bacterial butyrate mediates the anti-atherosclerotic effect of silybin. Biomed Pharmacother. (2023) 169:115916. 10.1016/j.biopha.2023.115916</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2023.115916</ArticleId><ArticleId IdType="pubmed">38000354</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Wang L, Bhat OM, Lohner H, Li PL. Differential effects of short chain fatty acids on endothelial Nlrp3 inflammasome activation and neointima formation: antioxidant action of butyrate. Redox Biol. (2018) 16:21&#x2013;31. 10.1016/j.redox.2018.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2018.02.007</ArticleId><ArticleId IdType="pmc">PMC5842312</ArticleId><ArticleId IdType="pubmed">29475132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, Yang L, Liu Y, Yan R, Wang R, Zhang P, et al. Butyrate suppresses atherosclerotic inflammation by regulating macrophages and polarization via GPR43/HDAC-miRNAs axis in ApoE-/- mice. PLoS One. (2023) 18:e0282685. 10.1371/journal.pone.0282685</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0282685</ArticleId><ArticleId IdType="pmc">PMC9994734</ArticleId><ArticleId IdType="pubmed">36888629</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Li R, You N, Zhao X, Li J, Jiang W. Butyric acid ameliorates myocardial fibrosis by regulating M1/M2 polarization of macrophages and promoting recovery of mitochondrial function. Front Nutr. (2022) 9:875473. 10.3389/fnut.2022.875473</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.875473</ArticleId><ArticleId IdType="pmc">PMC9159497</ArticleId><ArticleId IdType="pubmed">35662928</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Gao Z, Zhang J, Ye X, Xu A, Ye J, et al. Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes. (2012) 61:797&#x2013;806. 10.2337/db11-0846</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db11-0846</ArticleId><ArticleId IdType="pmc">PMC3314370</ArticleId><ArticleId IdType="pubmed">22338096</ArticleId></ArticleIdList></Reference><Reference><Citation>Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. (2015) 21:263&#x2013;9. 10.1038/nm.3804</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3804</ArticleId><ArticleId IdType="pmc">PMC4352123</ArticleId><ArticleId IdType="pubmed">25686106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Xu Y, Yang M, Zhang M, Xiao M, Li X. Butyrate mitigates TNF-alpha-induced attachment of monocytes to endothelial cells. J Bioenerg Biomembr. (2020) 52:247&#x2013;56. 10.1007/s10863-020-09841-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10863-020-09841-9</ArticleId><ArticleId IdType="pubmed">32588186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng D, Liu J, Piao H, Zhu Z, Wei R, Liu K. ROS-triggered endothelial cell death mechanisms: focus on pyroptosis, parthanatos, and ferroptosis. Front Immunol. (2022) 13:1039241. 10.3389/fimmu.2022.1039241</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1039241</ArticleId><ArticleId IdType="pmc">PMC9663996</ArticleId><ArticleId IdType="pubmed">36389728</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar EC, Santos LC, Leonel AJ, de Oliveira JS, Santos EA, Navia-Pelaez JM, et al. Oral butyrate reduces oxidative stress in atherosclerotic lesion sites by a mechanism involving NADPH oxidase down-regulation in endothelial cells. J Nutr Biochem. (2016) 34:99&#x2013;105. 10.1016/j.jnutbio.2016.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2016.05.002</ArticleId><ArticleId IdType="pubmed">27261536</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Q, Leung FP, Chen FM, Tian XY, Chen Z, Tse G, et al. Butyrate protects endothelial function through PPARdelta/miR-181b signaling. Pharmacol Res. (2021) 169:105681. 10.1016/j.phrs.2021.105681</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105681</ArticleId><ArticleId IdType="pubmed">34019979</ArticleId></ArticleIdList></Reference><Reference><Citation>Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci. (2016) 73:3221&#x2013;47. 10.1007/s00018-016-2223-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2223-0</ArticleId><ArticleId IdType="pmc">PMC4967105</ArticleId><ArticleId IdType="pubmed">27100828</ArticleId></ArticleIdList></Reference><Reference><Citation>He F, Ru X, Wen T. NRF2, A transcription factor for stress response and beyond. Int J Mol Sci. (2020) 21:4777. 10.3390/ijms21134777</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21134777</ArticleId><ArticleId IdType="pmc">PMC7369905</ArticleId><ArticleId IdType="pubmed">32640524</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JA, Rainbow RD, Sharma P. Mitigation of cardiovascular disease and toxicity through NRF2 signalling. Int J Mol Sci. (2023) 24:6723. 10.3390/ijms24076723</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24076723</ArticleId><ArticleId IdType="pmc">PMC10094784</ArticleId><ArticleId IdType="pubmed">37047696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganna K, Mathew OP, Yatsu FM, Yousefipour Z, Hayes BE, Milton SG. Involvement of glutathione/glutathione S-transferase antioxidant system in butyrate-inhibited vascular smooth muscle cell proliferation. FEBS J. (2007) 274:5962&#x2013;78. 10.1111/j.1742-4658.2007.06119.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2007.06119.x</ArticleId><ArticleId IdType="pubmed">17961182</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Qian Y, Jiang C, Tang L, Yu J, Zhang L, et al. Butyrate ameliorated ferroptosis in ulcerative colitis through modulating Nrf2/GPX4 signal pathway and improving intestinal barrier. Biochim Biophys Acta Mol Basis Dis. (2024) 1870:166984. 10.1016/j.bbadis.2023.166984</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2023.166984</ArticleId><ArticleId IdType="pubmed">38061600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew OP, Ranganna K, Milton SG. Involvement of the antioxidant effect and anti-inflammatory response in butyrate-inhibited vascular smooth muscle cell proliferation. Pharmaceuticals. (2014) 7:1008&#x2013;27. 10.3390/ph7111008</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph7111008</ArticleId><ArticleId IdType="pmc">PMC4246201</ArticleId><ArticleId IdType="pubmed">25390157</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W. GPX4: the hub of lipid oxidation, ferroptosis, disease and treatment. Biochim Biophys Acta Rev Cancer. (2023) 1878:188890. 10.1016/j.bbcan.2023.188890</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2023.188890</ArticleId><ArticleId IdType="pubmed">37001616</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Liu Y, Liao Y, Zhu C, Zou Z. GPX4, Ferroptosis, and diseases. Biomed Pharmacother. (2024) 174:116512. 10.1016/j.biopha.2024.116512</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2024.116512</ArticleId><ArticleId IdType="pubmed">38574617</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Xu C, Huang R, Song J, Li D, Xia M. Butyrate from pectin fermentation inhibits intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E-deficient mice. J Nutr Biochem. (2018) 56:175&#x2013;82. 10.1016/j.jnutbio.2018.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2018.02.011</ArticleId><ArticleId IdType="pubmed">29574331</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, et al. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. (2007) 116:1404&#x2013;12. 10.1161/CIRCULATIONAHA.106.684704</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.684704</ArticleId><ArticleId IdType="pubmed">17724261</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaidarov I, Chen X, Anthony T, Maciejewski-Lenoir D, Liaw C, Unett DJ. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential. Cell Signal. (2013) 25:2003&#x2013;16. 10.1016/j.cellsig.2013.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2013.06.008</ArticleId><ArticleId IdType="pubmed">23770183</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Li X, Su C, Xi M, Zhang X, Jiang Z, et al. Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice. Br J Pharmacol. (2020) 177:1754&#x2013;72. 10.1111/bph.14933</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14933</ArticleId><ArticleId IdType="pmc">PMC7070171</ArticleId><ArticleId IdType="pubmed">31769014</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, et al. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. (2019) 7:68. 10.1186/s40168-019-0683-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-019-0683-9</ArticleId><ArticleId IdType="pmc">PMC6486680</ArticleId><ArticleId IdType="pubmed">31027508</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Sun Z, Shali S, Mei Z, Chang S, Mo H, et al. The gut microbiome and microbial metabolites in acute myocardial infarction. J Genet Genomics. (2022) 49:569&#x2013;78. 10.1016/j.jgg.2021.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgg.2021.12.007</ArticleId><ArticleId IdType="pubmed">34974193</ArticleId></ArticleIdList></Reference><Reference><Citation>Talmor-Barkan Y, Bar N, Shaul AA, Shahaf N, Godneva A, Bussi Y, et al. Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease. Nat Med. (2022) 28:295&#x2013;302. 10.1038/s41591-022-01686-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01686-6</ArticleId><ArticleId IdType="pubmed">35177859</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M, Fan X, Tuerhongjiang G, Wang C, Wu H, Lou B, et al. Targeted metabolomic analysis of plasma fatty acids in acute myocardial infarction in young adults. Nutr Metab Cardiovasc Dis. (2021) 31:3131&#x2013;41. 10.1016/j.numecd.2021.06.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2021.06.024</ArticleId><ArticleId IdType="pubmed">34625358</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang TWH, Chen HC, Chen CY, Yen CYT, Lin CJ, Prajnamitra RP, et al. Loss of gut microbiota alters immune system composition and cripples postinfarction cardiac repair. Circulation. (2019) 139:647&#x2013;59. 10.1161/circulationaha.118.035235</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.118.035235</ArticleId><ArticleId IdType="pubmed">30586712</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HC, Liu YW, Chang KC, Wu YW, Chen YM, Chao YK, et al. Gut butyrate-producers confer post-infarction cardiac protection. Nat Commun. (2023) 14:7249. 10.1038/s41467-023-43167-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43167-5</ArticleId><ArticleId IdType="pmc">PMC10636175</ArticleId><ArticleId IdType="pubmed">37945565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng P, Zeng W, Li L, Huo D, Zeng L, Tan J, et al. PLGA-PNIPAM microspheres loaded with the gastrointestinal nutrient NaB ameliorate cardiac dysfunction by activating Sirt3 in acute myocardial infarction. Adv Sci. (2016) 3:1600254. 10.1002/advs.201600254</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.201600254</ArticleId><ArticleId IdType="pmc">PMC5157182</ArticleId><ArticleId IdType="pubmed">27981013</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Huang X, Tong Y, Gao H. Butyrate improves cardiac function and sympathetic neural remodeling following myocardial infarction in rats. Can J Physiol Pharmacol. (2020) 98:391&#x2013;9. 10.1139/cjpp-2019-0531</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/cjpp-2019-0531</ArticleId><ArticleId IdType="pubmed">31999473</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Liu D, Zhao L, Zhou D, Rong J, Zhang L, et al. Myocardial ischemia/reperfusion injury: mechanisms of injury and implications for management (review). Exp Ther Med. (2022) 23:430. 10.3892/etm.2022.11357</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2022.11357</ArticleId><ArticleId IdType="pmc">PMC9121204</ArticleId><ArticleId IdType="pubmed">35607376</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Xu R, Zhang K, Sun R, Yang M, Li K, et al. Characterization of early myocardial inflammation in ischemia-reperfusion injury. Front Immunol. (2022) 13:1081719. 10.3389/fimmu.2022.1081719</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1081719</ArticleId><ArticleId IdType="pmc">PMC9939645</ArticleId><ArticleId IdType="pubmed">36814859</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. (2008) 88:581&#x2013;609. 10.1152/physrev.00024.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00024.2007</ArticleId><ArticleId IdType="pmc">PMC3199571</ArticleId><ArticleId IdType="pubmed">18391174</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Li X, Song L. Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway. Pharm Biol. (2020) 58:655&#x2013;63. 10.1080/13880209.2020.1779318</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13880209.2020.1779318</ArticleId><ArticleId IdType="pmc">PMC7470075</ArticleId><ArticleId IdType="pubmed">32649845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Zhang K, Xu C, Chen Z, Jiang H. Anti-inflammatory effect of sodium butyrate preconditioning during myocardial ischemia/reperfusion. Exp Ther Med. (2014) 8:229&#x2013;32. 10.3892/etm.2014.1726</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2014.1726</ArticleId><ArticleId IdType="pmc">PMC4061237</ArticleId><ArticleId IdType="pubmed">24944626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SH. Tyrate and propionate, short chain fatty acids, attenuate myocardial damages by inhibition of apoptosis in a rat model of ischemia-reperfusion. J Korean Soc Appl Biol Chem. (2010) 53:570&#x2013;7. 10.3839/jksabc.2010.088</Citation><ArticleIdList><ArticleId IdType="doi">10.3839/jksabc.2010.088</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Han J, Chen H, Wang Y, Zhou L, Wang M, et al. Oral supplementation with butyrate improves myocardial ischemia/reperfusion injury via a gut-brain neural circuit. Front Cardiovasc Med. (2021) 8:718674. 10.3389/fcvm.2021.718674</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.718674</ArticleId><ArticleId IdType="pmc">PMC8495014</ArticleId><ArticleId IdType="pubmed">34631821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhang S, Li B, Luo Y, Gong Y, Jin X, et al. Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome. Cardiovasc Res. (2022) 118:785&#x2013;97. 10.1093/cvr/cvab114</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab114</ArticleId><ArticleId IdType="pubmed">33757127</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo K, Fang C, Liu Z, Fu Y, Liu Y, Liu L, et al. Commensal microbe-derived SCFA alleviates atrial fibrillation via GPR43/NLRP3 signaling. Int J Biol Sci. (2022) 18:4219&#x2013;32. 10.7150/ijbs.70644</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.70644</ArticleId><ArticleId IdType="pmc">PMC9274492</ArticleId><ArticleId IdType="pubmed">35844801</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Liu S, Wang X, Chen Y, Pang P, Yang Q, et al. Diabetic cardiomyopathy: clinical phenotype and practice. Front Endocrinol. (2022) 13:1032268. 10.3389/fendo.2022.1032268</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.1032268</ArticleId><ArticleId IdType="pmc">PMC9767955</ArticleId><ArticleId IdType="pubmed">36568097</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. (2018) 122:624&#x2013;38. 10.1161/circresaha.117.311586</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.117.311586</ArticleId><ArticleId IdType="pmc">PMC5819359</ArticleId><ArticleId IdType="pubmed">29449364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. (2020) 126:1501&#x2013;25. 10.1161/circresaha.120.315913</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.120.315913</ArticleId><ArticleId IdType="pmc">PMC7251974</ArticleId><ArticleId IdType="pubmed">32437308</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Zou J, Xu X, Zhou H, Sun X, Wu L, et al. Short-chain fatty acids combined with intronic DNA methylation of HIF3A: potential predictors for diabetic cardiomyopathy. Clin Nutr. (2021) 40:3708&#x2013;17. 10.1016/j.clnu.2021.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2021.04.007</ArticleId><ArticleId IdType="pubmed">34130016</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Du J, Zhao YT, Zhang L, Lv G, Zhuang S, et al. Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice. Cardiovasc Diabetol. (2015) 14:99. 10.1186/s12933-015-0262-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-015-0262-8</ArticleId><ArticleId IdType="pmc">PMC4527099</ArticleId><ArticleId IdType="pubmed">26245924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wang J, Zhu X, Hu J, Liu C, Liu L. Energy metabolism and redox balance: how phytochemicals influence heart failure treatment. Biomed Pharmacother. (2024) 171:116136. 10.1016/j.biopha.2024.116136</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2024.116136</ArticleId><ArticleId IdType="pubmed">38215694</ArticleId></ArticleIdList></Reference><Reference><Citation>Carley AN, Maurya SK, Fasano M, Wang Y, Selzman CH, Drakos SG, et al. Short-chain fatty acids outpace ketone oxidation in the failing heart. Circulation. (2021) 143:1797&#x2013;808. 10.1161/CIRCULATIONAHA.120.052671</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.052671</ArticleId><ArticleId IdType="pmc">PMC8096711</ArticleId><ArticleId IdType="pubmed">33601938</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao F, Tian M, Zhang X, Jin X, Jiang Y, Sun X, et al. Butyrate enhances CPT1A activity to promote fatty acid oxidation and iTreg differentiation. Proc Natl Acad Sci U S A. (2021) 118:e2014681118. 10.1073/pnas.2014681118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2014681118</ArticleId><ArticleId IdType="pmc">PMC8179238</ArticleId><ArticleId IdType="pubmed">34035164</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Deng M, Lu A, Chen Y, Chen Y, Wu C, et al. Sodium butyrate attenuates angiotensin II-induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6-dependent mechanism. J Cell Mol Med. (2019) 23:8139&#x2013;50. 10.1111/jcmm.14684</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.14684</ArticleId><ArticleId IdType="pmc">PMC6850921</ArticleId><ArticleId IdType="pubmed">31565858</ArticleId></ArticleIdList></Reference><Reference><Citation>Seefeldt JM, Homilius C, Hansen J, Lassen TR, Jespersen NR, Jensen RV, et al. Short-chain fatty acid butyrate is an inotropic agent with vasorelaxant and cardioprotective properties. J Am Heart Assoc. (2024) 13:e033744. 10.1161/JAHA.123.033744</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.123.033744</ArticleId><ArticleId IdType="pmc">PMC11179878</ArticleId><ArticleId IdType="pubmed">38686853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren A, Dikaiou P. Cardiovascular outcomes in type 1 and type 2 diabetes. Diabetologia. (2023) 66:425&#x2013;37. 10.1007/s00125-022-05857-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-022-05857-5</ArticleId><ArticleId IdType="pmc">PMC9840171</ArticleId><ArticleId IdType="pubmed">36640192</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain WD, Paldanius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. (2018) 17:57. 10.1186/s12933-018-0703-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-018-0703-2</ArticleId><ArticleId IdType="pmc">PMC5905152</ArticleId><ArticleId IdType="pubmed">29669543</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AW, Jandeleit-Dahm KAM. Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches. Nat Rev Cardiol. (2025) 22:482&#x2013;96. 10.1038/s41569-024-01115-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-024-01115-w</ArticleId><ArticleId IdType="pubmed">39805949</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. (2021) 143:e984&#x2013;e1010. 10.1161/CIR.0000000000000973</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000973</ArticleId><ArticleId IdType="pmc">PMC8493650</ArticleId><ArticleId IdType="pubmed">33882682</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcelin G, Gautier EL, Clement K. Adipose tissue fibrosis in obesity: etiology and challenges. Annu Rev Physiol. (2022) 84:135&#x2013;55. 10.1146/annurev-physiol-060721-092930</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-060721-092930</ArticleId><ArticleId IdType="pubmed">34752708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. (2014) 15:6184&#x2013;223. 10.3390/ijms15046184</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms15046184</ArticleId><ArticleId IdType="pmc">PMC4013623</ArticleId><ArticleId IdType="pubmed">24733068</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, Clark JM, et al. 
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a <i>post-hoc</i> analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. (2016) 4:913&#x2013;21. 10.1016/s2213-8587(16)30162-0
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-8587(16)30162-0</ArticleId><ArticleId IdType="pmc">PMC5094846</ArticleId><ArticleId IdType="pubmed">27595918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. (2019) 380:347&#x2013;57. 10.1056/NEJMoa1812389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1812389</ArticleId><ArticleId IdType="pubmed">30415602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes AC, Hoffmann C, Mota JF. The human gut microbiota: metabolism and perspective in obesity. Gut Microbes. (2018) 9:308&#x2013;25. 10.1080/19490976.2018.1465157</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2018.1465157</ArticleId><ArticleId IdType="pmc">PMC6219651</ArticleId><ArticleId IdType="pubmed">29667480</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH, et al. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. (2020) 11:571731. 10.3389/fimmu.2020.571731</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.571731</ArticleId><ArticleId IdType="pmc">PMC7596417</ArticleId><ArticleId IdType="pubmed">33178196</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Radjabzadeh D, Chen L, Kurilshikov A, Kavousi M, Ahmadizar F, et al. Association of insulin resistance and type 2 diabetes with gut microbial diversity: a microbiome-wide analysis from population studies. JAMA Netw Open. (2021) 4:e2118811. 10.1001/jamanetworkopen.2021.18811</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.18811</ArticleId><ArticleId IdType="pmc">PMC8322996</ArticleId><ArticleId IdType="pubmed">34323983</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Ramesh G, Wu M, Jensen ET, Crago O, Bertoni AG, et al. Butyrate-producing bacteria and insulin homeostasis: the microbiome and insulin longitudinal evaluation study (MILES). Diabetes. (2022) 71:2438&#x2013;46. 10.2337/db22-0168</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db22-0168</ArticleId><ArticleId IdType="pmc">PMC9630078</ArticleId><ArticleId IdType="pubmed">35972231</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers AC, Philippe J, Hermann H, Habener JF. Sodium butyrate increases glucagon and insulin gene expression by recruiting immunocytochemically negative cells to produce hormone. Diabetes. (1988) 37:1405&#x2013;10. 10.2337/diab.37.10.1405</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.37.10.1405</ArticleId><ArticleId IdType="pubmed">2843409</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Yuan M, Zhang L, Zhu K, Sheng C, Zhou F, et al. Sodium butyrate potentiates insulin secretion from rat islets at the expense of compromised expression of &#x3b2; cell identity genes. Cell Death Dis. (2022) 13:67. 10.1038/s41419-022-04517-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04517-1</ArticleId><ArticleId IdType="pmc">PMC8770496</ArticleId><ArticleId IdType="pubmed">35046383</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Liu J, Yuan Y, Chen J, Cheng S, Wang H, et al. Sodium butyrate mitigates type 2 diabetes by inhibiting PERK-CHOP pathway of endoplasmic reticulum stress. Environ Toxicol Pharmacol. (2018) 64:112&#x2013;21. 10.1016/j.etap.2018.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.etap.2018.09.002</ArticleId><ArticleId IdType="pubmed">30342372</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan M, Li X, Sun C, Tan J, Liu Y, Li M, et al. Sodium butyrate attenuates AGEs-induced oxidative stress and inflammation by inhibiting autophagy and affecting cellular metabolism in THP-1 cells. Molecules. (2022) 27:8715. 10.3390/molecules27248715</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27248715</ArticleId><ArticleId IdType="pmc">PMC9781837</ArticleId><ArticleId IdType="pubmed">36557849</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Jena GB. Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat. Chem Biol Interact. (2014) 213:1&#x2013;12. 10.1016/j.cbi.2014.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2014.02.001</ArticleId><ArticleId IdType="pubmed">24530320</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibowo H, Harbuwono DS, Tahapary DL, Kartika R, Pradipta S, Larasati RA. Impact of sodium butyrate treatment in LPS-stimulated peripheral blood mononuclear cells of poorly controlled type 2 DM. Front Endocrinol. (2021) 12:652942. 10.3389/fendo.2021.652942</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.652942</ArticleId><ArticleId IdType="pmc">PMC8358792</ArticleId><ArticleId IdType="pubmed">34393993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. (2009) 58:1509&#x2013;17. 10.2337/db08-1637</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db08-1637</ArticleId><ArticleId IdType="pmc">PMC2699871</ArticleId><ArticleId IdType="pubmed">19366864</ArticleId></ArticleIdList></Reference><Reference><Citation>Henagan TM, Stefanska B, Fang Z, Navard AM, Ye J, Lenard NR, et al. Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation, obesity and insulin resistance through nucleosome positioning. Br J Pharmacol. (2015) 172:2782&#x2013;98. 10.1111/bph.13058</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13058</ArticleId><ArticleId IdType="pmc">PMC4439875</ArticleId><ArticleId IdType="pubmed">25559882</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. (2014) 156:84&#x2013;96. 10.1016/j.cell.2013.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.12.016</ArticleId><ArticleId IdType="pubmed">24412651</ArticleId></ArticleIdList></Reference><Reference><Citation>van Deuren T, Blaak EE, Canfora EE. Butyrate to combat obesity and obesity-associated metabolic disorders: current status and future implications for therapeutic use. Obes Rev. (2022) 23:e13498. 10.1111/obr.13498</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.13498</ArticleId><ArticleId IdType="pmc">PMC9541926</ArticleId><ArticleId IdType="pubmed">35856338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HV, Frassetto A, Kowalik EJ, Jr, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One. (2012) 7:e35240. 10.1371/journal.pone.0035240</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0035240</ArticleId><ArticleId IdType="pmc">PMC3323649</ArticleId><ArticleId IdType="pubmed">22506074</ArticleId></ArticleIdList></Reference><Reference><Citation>Roshanravan N, Mahdavi R, Alizadeh E, Jafarabadi MA, Hedayati M, Ghavami A, et al. Effect of butyrate and inulin supplementation on glycemic status, lipid profile and glucagon-like peptide 1 level in patients with type 2 diabetes: a randomized double-blind, placebo-controlled trial. Horm Metab Res. (2017) 49:886&#x2013;91. 10.1055/s-0043-119089</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0043-119089</ArticleId><ArticleId IdType="pubmed">28962046</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios T, Vitetta L, Coulson S, Madigan CD, Lam YY, Manuel R, et al. Targeting the intestinal microbiota to prevent type 2 diabetes and enhance the effect of metformin on glycaemia: a randomised controlled pilot study. Nutrients. (2020) 12:2041. 10.3390/nu12072041</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12072041</ArticleId><ArticleId IdType="pmc">PMC7400852</ArticleId><ArticleId IdType="pubmed">32660025</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Jena G. Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: a comparative study with metformin. Chem Biol Interact. (2016) 254:124&#x2013;34. 10.1016/j.cbi.2016.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2016.06.007</ArticleId><ArticleId IdType="pubmed">27270450</ArticleId></ArticleIdList></Reference><Reference><Citation>De Groot PF, Nikolic T, Imangaliyev S, Bekkering S, Duinkerken G, Keij FM, et al. Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. Diabetologia. (2020) 63:597&#x2013;610. 10.1007/s00125-019-05073-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-019-05073-8</ArticleId><ArticleId IdType="pubmed">31915895</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar EC, da Silva JF, Navia-Pelaez JM, Leonel AJ, Lopes LG, Menezes-Garcia Z, et al. Sodium butyrate modulates adipocyte expansion, adipogenesis, and insulin receptor signaling by upregulation of PPAR-gamma in obese apo E knockout mice. Nutrition. (2018) 47:75&#x2013;82. 10.1016/j.nut.2017.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2017.10.007</ArticleId><ArticleId IdType="pubmed">29429540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Peng K, Zhao Y, Xu C, Tao X, Liu Y, et al. Sodium butyrate attenuated diet-induced obesity, insulin resistance and inflammation partly by promoting fat thermogenesis via intro-adipose sympathetic innervation. Front Pharmacol. (2022) 13:938760. 10.3389/fphar.2022.938760</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.938760</ArticleId><ArticleId IdType="pmc">PMC9574364</ArticleId><ArticleId IdType="pubmed">36263123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F, Lv YW, Long J, Chen JM, He JM, Ruan XZ, et al. Butyrate improves the metabolic disorder and gut microbiome dysbiosis in mice induced by a high-fat diet. Front Pharmacol. (2019) 10:1040. 10.3389/fphar.2019.01040</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.01040</ArticleId><ArticleId IdType="pmc">PMC6761375</ArticleId><ArticleId IdType="pubmed">31607907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. (2013) 4:1829. 10.1038/ncomms2852</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2852</ArticleId><ArticleId IdType="pmc">PMC3674247</ArticleId><ArticleId IdType="pubmed">23652017</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Yi CX, Katiraei S, Kooijman S, Zhou E, Chung CK, et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut. (2018) 67:1269&#x2013;79. 10.1136/gutjnl-2017-314050</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2017-314050</ArticleId><ArticleId IdType="pubmed">29101261</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitt J, Woo V, Lee P, Moncivaiz J, Haberman Y, Denson L, et al. Disruption of epithelial HDAC3 in intestine prevents diet-induced obesity in mice. Gastroenterology. (2018) 155:501&#x2013;13. 10.1053/j.gastro.2018.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.04.017</ArticleId><ArticleId IdType="pmc">PMC6067972</ArticleId><ArticleId IdType="pubmed">29689264</ArticleId></ArticleIdList></Reference><Reference><Citation>Honma K, Oshima K, Takami S, Goda T. Regulation of hepatic genes related to lipid metabolism and antioxidant enzymes by sodium butyrate supplementation. Metabol Open. (2020) 7:100043. 10.1016/j.metop.2020.100043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2020.100043</ArticleId><ArticleId IdType="pmc">PMC7424775</ArticleId><ArticleId IdType="pubmed">32812944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori Y, Tsutsui S, Yamada C, Kobayashi Y, Nakagawa T, Shimada M. Dietary supplementation with sodium butyrate reduces high-sucrose diet-induced hepatic accumulation of triacylglycerols and expression of fatty acid synthesis enzymes in rats. J Oleo Sci. (2022) 71:1189&#x2013;93. 10.5650/jos.ess22112</Citation><ArticleIdList><ArticleId IdType="doi">10.5650/jos.ess22112</ArticleId><ArticleId IdType="pubmed">35922931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao ZH, Wang ZX, Zhou D, Han Y, Ma F, Hu Z, et al. Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene. Cell Mol Gastroenterol Hepatol. (2021) 12:857&#x2013;71. 10.1016/j.jcmgh.2021.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2021.05.006</ArticleId><ArticleId IdType="pmc">PMC8346675</ArticleId><ArticleId IdType="pubmed">33989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, Hernandez MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Sci Rep. (2019) 9:12515. 10.1038/s41598-019-48775-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48775-0</ArticleId><ArticleId IdType="pmc">PMC6715624</ArticleId><ArticleId IdType="pubmed">31467327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SC, Xu Z, Mak JWY, Yang K, Liu Q, Zuo T, et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut. (2022) 71:716&#x2013;23. 10.1136/gutjnl-2020-323617</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323617</ArticleId><ArticleId IdType="pubmed">33785557</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola S, Nocerino R, Paparo L, Bedogni G, Calignano A, Di Scala C, et al. Therapeutic effects of butyrate on pediatric obesity: a randomized clinical trial. JAMA Netw Open. (2022) 5:e2244912. 10.1001/jamanetworkopen.2022.44912</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.44912</ArticleId><ArticleId IdType="pmc">PMC9855301</ArticleId><ArticleId IdType="pubmed">36469320</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon H-R, Yun J-M. Sodium butyrate inhibits high glucose-induced inflammation by controlling the acetylation of NF-&#x3ba;B p65 in human monocytes. Nutr Res Pract. (2023) 17(1):164&#x2013;73. 10.4162/nrp.2023.17.1.164</Citation><ArticleIdList><ArticleId IdType="doi">10.4162/nrp.2023.17.1.164</ArticleId><ArticleId IdType="pmc">PMC9884585</ArticleId><ArticleId IdType="pubmed">36777806</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>